FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Listens: 0

About

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

February 27, 2020

Science

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.